NCT05557370View on ClinicalTrials.gov

Immunogenicity of HPV Vaccine in Transplant Recipients.

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2035

Conditions
Chronic Kidney DiseasesKidney Transplant
Interventions
BIOLOGICAL

Human Papilloma Virus vaccine (GARDASIL 9)

Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).

Trial Locations (1)

53226

Froedtert Lutheran Memorial Hospital, Milwaukee

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical College of Wisconsin

OTHER